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Purpose: The incidence of differentiated thyroid cancer is increasing in young
adults and females in Korea. Some of them experience short-term hypothyroidism
in preparation for radioiodine (RAI) therapy, which can have a deleterious effect on
the cardiovascular system. However, it is not clear if short-term hypothyroidism
induces endothelial dysfunction in patients with low cardiovascular risk. Therefore,
the aim of this study was to investigate whether short-term hypothyroidism is
associated with endothelial dysfunction in patients with low cardiovascular risk.
Materials and Methods: To evaluate the effect of short-term hypothyroidism on
endothelial function in this group, we recruited fifteen female patients with low
cardiovascular risk. We analyzed clinical, biochemical, and cardiovascular
parameters at four time points: the last day on levothyroxine (LT4) at their usual
thyroid-stimulating hormone (TSH)-suppressive doses (P1), 7 days (P2) & 4 weeks
(P3) after withdrawal of LT4, and 8 weeks (P4) after replacement of the previous
dose of LT4. A high resolution ultrasound was used to measure brachial artery
diameter at rest, after reactive hyperemia, and after sublingual nitroglycerin.
Results: During short-term hypothyroidism (P3), serum concentrations of total
cholesterol and low-density lipoprotein (LDL)-cholesterol were increased (p <
0.001 for each period). In spite of having worsened lipid states, serum high
sensitivity C-reactive protein or flow-mediated vasodilatation, which is one of the
surrogate markers of the endothelial function, did not change during short-term
hypothyroidism. Conclusion: Short-term hypothyroidism induced worsening of
metabolic parameters, but not enough to induce the endothelial dysfunction in
patients with low cardiovascular risk.
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thyroid remnant ablation and remnant disease treatment.1,2
A high level of thyroid-stimulating hormone (TSH) is re-
quired to stimulate sufficient radioiodine uptake for therapy.
This can be obtained either by withdrawal of thyroid
hormone or by the injection of recombinant human TSH
(Thyrogen®, Genzyme, Allston, MA, USA); the prior
method is more commonly used. Therefore, during RAI
therapy, most patients experience varied states of thyroid
disease, ranging from subclinical hyperthyroidism to short-
term hypothyroidism. 
Atherosclerosis is a chronic disease that makes arterial
walls thick and less elastic. The resulting restriction of
blood flow can lead to various problems such as heart at-
tacks, stroke, and other serious cardiovascular complica-
tions. Overt hypothyroidism is associated with cardiovas-
cular disease mortality and it is a well-known risk factor of
atherosclerosis. The  atherosclerosis is induced through the
aggravation of lipid profiles, insulin resistance, hyperten-
sion, arterial stiffness, and endothelial dysfunction in
hypothyroid states.3-5 However, the effect of short-term
hypothyroidism on atherosclerosis or cardiovascular
disease is not clear yet.
Erbil, et al.6 reported that short-term hypothyroidism
induces endothelial dysfunction and recovers after correc-
ting the hypothyroid state, although there were no clinical
cardiovascular events during their study. In the study, the
Turkish people were overweight [body mass index (BMI)
28.8 ± 3.7 kg/m2] and had higher levels of cholesterol at
the baseline compared with our patients.6 Considering that
cardiovascular disease is affected by many environmental
and genetic factors, further studies are warranted to apply
the previous results to the Korean population. The inci-
dence of thyroid cancer is increasing in Korea, especially
in women, who have a relatively lower cardiovascular risk
than men.7 Thus, we evaluated endothelial function and
metabolic parameters before and after levothyroxine (LT4)
withdrawal prior to RAI therapy in a single cohort of
Korean female patients with differentiated thyroid cancer
who did not have well-established metabolic risk factors.
Subjects and study protocols
Fifteen female patients with differentiated thyroid cancer
treated by bilateral total or near-total thyroidectomy were
included in this prospective study (age 49.1 ± 7.2 years;
range 38-62 years). All patients were non-smokers. Before
the recruitment, none of the patients had clinically detec-
table diabetes, hypertension, coronary artery disease, renal
disease, liver disease, or familial hypercholesterolemia.
They also had no family history of cardiovascular disease. 
All patients were treated by withdrawal of LT4 for 4
weeks. This procedure resulted in serum TSH levels higher
than 30 mU/L in all patients. Each patient was evaluated at
four time points: the last day on LT4 at their usual TSH-
suppressive doses (P1), 7 days after withdrawal (P2), the
day of RAI therapy (P3), and 8 weeks after RAI therapy
(P4). The previous dose of LT4 restarted after RAI thera-
py. Evaluations included measurements of physical, bio-
chemical, and cardiovascular parameters.
After a 12-hour fast, blood was collected from participants
and immediately centrifuged. Sera were stored at -70˚C
and measured after all patients had completed their follow-
up (P4). The Institutional Review Board of the Seoul
National University Bundang Hospital approved the study
protocol, and written informed consent was obtained from
all subjects.
Anthropometric and body fat measurements
The subjects’ height and weight were measured using an
automatic height-weight scale while they wore light
clothing. BMI was then calculated as the ratio between
weight and height squared (kg/m2). Blood pressure was
measured four times on each occasion using a standard
mercury sphygmomanometer after 10 minutes rest during
which the subject was sitting. Waist circumference was
measured at the narrowest point between the lower border
of the rib cage and the iliac crest. Hip circumference was
measured at the level of the symphysis pubis and the grea-
test gluteal protuberance. The waist to hip ratio was then
calculated by dividing waist circumference by hip circum-
ference.
The percentages of body fat and lean body mass were
measured using a tetrapolar bioelectrical impedance analy-
zer (Inbody 3.0®, Biospace, Seoul, Korea). Bioelectrical
impedance measures two parameters, fat and lean tissue,
using empirically derived formulas that have been validat-
ed, and yield they estimates that correlate with estimates
obtained using underwater weighing.
Measurements of thyroid function and metabolic 
parameters
The serum TSH and free T4 concentrations were measured
by immunoradiometric assays using commercial kits
(TSH, CIS bio international, Gif-sur-Yvette, France; free
T4, DiaSorin S.p.A, Saluggia, Italy). The normal ranges
were 0.4-4.1 mIU/L for serum TSH and 0.7-1.8 ng/dL for
free T4, as reported by the Central Laboratory of Seoul
National University Bundang Hospital. Total cholesterol,
triglyceride, and high-density lipoprotein (HDL)-choles-
terol concentrations were measured enzymatically using
the TBA-200FR system (Toshiba, Tokyo, Japan) according
to the manufacturer’s instructions. Serum low-density
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lipoprotein (LDL)-cholesterol levels were calculated using
Friedewald’s equation: LDL = total cholesterol-HDL-
triglyceride/5. The apolipoprotein A and apolipoprotein B
concentrations were measured using immunoturbidimetric
assays (Randox, Crumlin, UK) on the 502X system (A&T,
Tokyo, Japan). High sensitive-C-reactive protein (hs-CRP)
was measured using a highly sensitive particle enhanced
light-scattering immunoassay (Denka Seiken, Tokyo,
Japan) on the TBA-200FR system according to the manu-
facturer’s instructions. 
Vascular studies
The vascular studies of the brachial artery were performed
noninvasively, as described previously,8,9 at each of the
four stages (P1, 2, 3, 4). Patients were investigated by high-
resolution imaging of the brachial artery of the dominant
arm using a 15 MHz linear array probe (Sonos 7500,
Philips Medical Systems, Andover, MA, USA) to assess
endothelial responses. A sphygmomanometer cuff was
placed between the elbow and hand. The brachial artery
internal diameter was measured from the anterior to the
posterior “m” line, the interface between media and ad-
ventia, at the end-diastole gated on the R wave of the elec-
trocardiogram (ECG). For the reactive hyperemia scan,
another diameter measurement was taken 45-60 s after
cuff deflation. Four cardiac cycles were analyzed for each
scan and the measurements were averaged. In each patient,
scans were taken at rest, during reactive hyperemia (with
increased flow induced by inflation and then deflation of a
sphygmomanometer cuff around the limb, distal to the
scanned part of the artery), again at rest, and after adminis-
tration of sublingual nitroglycerin (an endothelium-inde-
pendent smooth muscle mediated vasodilatation). The
subjects rested in supine position for at least 10 min before
the first resting scan was recorded. Increased flow was
then induced by inflating a pneumatic tourniquet to a
pressure of 300 mmHg for 5 min. The second scan was
taken 45-60 s after cuff deflation. A time interval of 15
min was allowed for vessel recovery, and consecutive rest-
ing scans were taken. Sublingual nitroglycerin (0.6 mg)
was then administered, and 3 min later, the final scan was
performed. Each vessel diameter in scans after reactive
hyperemia, 15 min at rest, and with nitroglycerin was cal-
culated in percentages of the first control scan, that is, %
diameter changes = [Vessel Diameter (during reactive
hyperemia or after nitroglycerin) - Vessel Diameter (rest-
ing)]/vessel diameter (resting). Each Doppler examination
was performed by the same investigator who was unaware
of the laboratory values at the time of the examination.
Statistical analysis
Data are reported as mean (s.d.). Differences between
continuous variables before and after treatment were com-
pared by means of repeated measures ANOVA [general
linear model (GLM) procedure in SPSS]. Prior to ANOVA
procedures, the assumption of sphericity was tested with
Mauchly’s test. When the sphericity assumption was not
met, the multivariate test statistic was determined using
Wilks’ lambda test for significance testing. For comparing
the profiles at P1 and P4, the nonparametric Wilcoxon’s
rank test was used for paired samples. Results were con-
sidered statistically significant at p < 0.05. All data were
analyzed using the Statistical Package for the Social
Sciences (SPSS® 12.0 for Windows, SPSS, Chicago, IL,
USA).
Changes of thyroid function 
As expected with chronic treatment with supraphysiol-
ogical doses of LT4, the mean serum thyroid hormone
RESULTS
Table 1. Effect of Thyroid Dysfunction on Physical Parameters
P1 P2 P3 P4 p value
Free T4 (ng/dL) 2.31 ± 0.43 1.18 ± 0.41 0.20 ± 0.06 2.70 ± 1.03 < 0.001
TSH (mU/L) 0.15 ± 0.29 0.35 ± 0.48 139.35 ± 37.82 0.54 ± 1.73 < 0.001
HR (/min) 69.3 ± 10.5 65.9 ± 11.1 59.4 ± 10.5 68.5 ± 9.0 < 0.001
SBP (mmHg) 114.8 ± 9.6 112.0 ± 8.5 112.3 ± 10.0 110.2 ± 12.3 0.003
DBP(mmHg) 70.0 ± 7.8 68.4 ± 7.4 67.7 ± 6.5 60.9 ± 7.8 < 0.001
Weight (kg) 59.3 ± 12.9 59.2 ± 13.1 60.2 ± 13.0 59.5 ± 12.8 0.082
BMI (kg/m2) 23.6 ± 4.6 23.6 ± 4.7 23.8 ± 4.9 23.5 ± 4.8 0.612
WC (cm) 78.0 ± 12.0 78.5 ± 12.5 79.2 ± 12.6 78.6 ± 12.4 0.075
HC (cm) 96.3 ± 9.4 96.1 ± 9.5 96.9 ± 9.2 96.4 ± 9.1 0.08
WHR 0.88 ± 0.07 0.88 ± 0.07 0.88 ± 0.07 0.88 ± 0.07 0.149
Fat mass (kg) 18.3 ± 8.3 18.1 ± 8.3 18.1 ± 8.5 18.2 ± 8.1 0.303
BMI, body mass index; WC, waist circumference; HC, hip circumference; WHR, waist-hip ratio.
Data are presented as means ± SD.
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levels were in the mild hyperthyroid range at the first
evaluation (P1) (Table 1).
At the second visit (P2: 1 week after LT4 withdrawal),
the mean TSH level was below the normal range, whereas
the mean serum free T4 was within the normal range. At
the third time point (P3), all patients presented with an
increased serum TSH (139.35 ± 37.82 mU/L) and low
serum free T4 (0.20 ± 0.06 ng/dL) levels (p < 0.001, res-
pectively).
At the fourth time point (P4: 8 weeks after LT4 resump-
tion), all patients had recovered from the short-term hypo-
thyroidism. Some patients did not show suppressed TSH
levels despite supraphysiological LT4 treatment. However,
there was no difference in serum TSH (p = 0.556) and free
T4 (p = 0.177) levels between P1 and P4.
Changes in anthropometric parameters
As shown in Table 1, the heart rate significantly decreased
during short-term hypothyroidism (P3) compared to P1
(59.4 ± 10.5 vs. 69.3 ± 10.5 beats/min, p < 0.001). Systolic
and diastolic blood pressures significantly decreased as the
study went on (i.e., blood pressure was highest at P1,
lowest at P4), but the differences in blood pressure at each
time were negligible. There was a trend that short-term
hypothyroidism increased body weight, waist circum-
ference, and hip circumferences, but the changes were not
statistically significant. The other physiologic findings of
fat mass, BMI, and waist-hip ratio did not change through-
out the study in spite of thyroid dysfunction.
Changes in lipid profiles
The levels of total cholesterol, apolipoprotein B, and LDL-
cholesterol significantly increased during the short-term
hypothyroidism and they improved after reversal of the
acute hypothyroidism (Table 2). However, the level of
HDL-cholesterol significantly increased during short-term
hypothyroidism (p < 0.001).
Changes in parameters representing endothelial 
functions
Serum hsCRP levels did not change throughout the study
(p = 0.322). Both flow-mediated dilatation (FMD) and
nitroglycerin-mediated dilatation (NMD) were measured
at each time point; however, there were no differences
Table 2. Effect of Thyroid Dysfunction on Lipid Profiles
P1 P2 P3 P4 p value
Cholesterol (mg/dL) 170.6 ± 39.9 180.9 ± 46.0 238.8 ± 48.7 165.4 ± 30.3 < 0.001
Triglyceride (mg/dL) 87.8 ± 44.0 99.4 ± 32.3 121.0 ± 56.0 95.1 ± 47.2 0.055
HDL-Chol (mg/dL) 58.6 ± 13.8 56.4 ± 9.5 68.4 ± 11.5 56.6 ± 13.1 < 0.001
LDL-Chol (mg/dL) 95.4 ± 35.7 106.0 ± 43.9 146.5 ± 48.3 90.3 ± 29.1 < 0.001
ApoA (mg/dL) 154.6 ± 39.0 147.6 ± 25.4 169.6 ± 29.8 160.5 ± 34.9 0.128
ApoB (mg/dL) 72.1 ± 28.2 79.5 ± 34.1 102.6 ± 28.4 73.6 ± 21.4 < 0.001
hs-CRP (mg/dL) 0.07 ± 0.14 0.03 ± 0.05 0.01 ± 0.00 0.05 ± 0.08 0.322
Glucose (mg/dL) 94.2 ± 9.0 95.0 ± 11.8 92.7 ± 9.4 96.6 ± 7.5 0.551
HDL, high-density lipoprotein; LDL, low-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein. 
Serum LDL levels were calculated using Friedewald’s equation.
Data are presented as means ± SD.
Fig 1. Effect of thyroid dysfunction on endothelial function. (A) Flow-mediated arterial dilatation (FMD) (endothelin-dependent vasodilatation) and
(B) nitroglycerin-mediated dilatation (NMD) (endothelin-independent vasodilatation) was measured at each of the four stages (P1, 2, 3, 4).
Differences between continuous variables before and after treatment were compared by means of repeated measures ANOVA. Median values,
interqurtile ranges, and ranges are denoted by horizontal bars, boxes, and error bars.
A B
according to thyroid status (Fig. 1). There were no clinical
cardiovascular events during the study. 
This study was designed to show whether the changes of
metabolic parameters during short-term hypothyroidism
resulting from LT4 withdrawal could affect endothelial
function in patients with low cardiac risk. This study
showed that short-term hypothyroidism had deleterious
effects on lipid metabolism, but not endothelial function in
patients with low cardiovascular risk.
It is very important for clinicians to know whether LT4
withdrawal for RAI in differentiated thyroid cancer pati-
ents can aggravate or initiate ischemic insults to the heart,
because ischemic heart disease causes serious morbidity
and mortality. Ischemic heart disease is mainly caused by
atherosclerotic changes in arteries, and atherosclerosis
begins from the innermost layer of the artery (the intima)
by inflammatory processes, i.e. endothelial dysfunction.10
Thus, endothelial functions are used to assess cardiovas-
cular risk by many researchers. FMD is known to be a
reliable and reproducible noninvasive measure of vascular
endothelial function.11 Although our study limited because
we measured endothelial function not by intraarterial phar-
macologic stimulation but by FMD, endothelial function
assessed by FMD correlates significantly with invasive
testing of coronary endothelial function as well as with the
severity and extent of coronary atherosclerosis.11 Thus,
noninvasive FMD provides valuable information into
vascular changes associated with early atherogenesis and
this merit led to our study.
It is well known that overt hypothyroidism increases the
total cholesterol level and LDL-cholesterol because of
decreased fractional clearance of LDL due to a reduced
number of LDL receptors in the liver.12 It is also establi-
shed that endothelial dysfunction acts as a promoter of
atherosclerosis and is associated with an increased risk of
cardiovascular events.13,14 Many studies have demonstrated
that thyroid hormone replacement improves intima-media
thickness, arterial stiffness, and endothelial dysfunction in
chronically hypothyroid patients,5,15-18 including patients
with subclinical hypothyroidism.18,19 Thyroid hormones are
considered to have direct vasodilatory effects on vascular
smooth muscle cells, and may exert part of their vascular
effects through an endothelium-mediated mechanism.6
Thus, these findings suggest that overt hypothyroidism is
associated with atherosclerosis initiating by endothelial
dysfunction. 
There are data about the effects of short-term hypothy-
roidism on the cardiovascular system; however, most
studies focused on the functions relating to ECG changes,
pump performance, and echocardiographic changes.3,20-22
Only two studies reported the association between short-
term hypothyroidism and endothelial dysfunction, and
showed that short-term hypothyroidism aggravated lipid
profiles and FMD.6,23
As expected, the results of this study correspond with the
earlier studies that short-term hypothyroidism increased
total and LDL-cholesterol.3,6,22-24 In addition, these abnor-
malities improved after LT4 treatment, as seen in other
studies. However, our results failed to show changes in
endothelial function according to the degree of thyroid
function. There was no difference in FMD (%) between P3
(7.32 ± 2.26%) and P4 (7.61 ± 2.48%). We estimated the
sample size (the number of patients = 15) from the previous
data6,23 (i.e., mean FMD = 12.0, SD = 3.0, expected dif-
ference = 0.2) at α = 0.05 and power (1-β) = 0.8. We could
not find any FMD change during hypothyroid states due to
a discrepancy between expected data and obtained data.
Lesser changes could have been missed due to a small
FMD (%) difference between hypothyroid and hyperthy-
roid states.
One of the possible reasons of the discrepancy is the
different metabolic risk among these groups. Compared to
our patients, the Turkish patients (n = 22) had higher levels
of total and LDL-cholesterol at baseline. These differences
were maintained during overt hypothyroidism in the Turkish
group,6 which means that the Turkish group was exposed
to more atherogenic conditions. Furthermore, our group
had higher HDL-cholesterol (68.4 ± 11.5 mg/dL) during
short-term hypothyroidism than those of Turkish group
(43.9 ± 8.8 mg/dL). As higher HDL-cholesterol is known
for numerous beneficial effects including improvement of
endothelial function, anti-inflammatory, anti-thrombotic,
antioxidative effects, and the stimulation of endothelial
regeneration,25 it may reverse the endothelial dysfunction
during short-term hypothyroidism. Being overweight and
relatively hypercholesterolemia might influence endo-
thelial dysfunction, even when a clinical disease has not
yet developed. In addition, the small number of subjects
and their ethnicity may have contributed to the differing
results. The difference between the Chinese group and
ours can be explained by HDL-cholesterol concentration.
The Chinese group (n = 12)23 that showed a negative
correlation between TSH and FMD had a relatively lower
concentration of HDL-cholesterol compared to ours.
Based on large-scale epidemiological and prospective
hormone treatment trials, CRP, a marker of inflammation,
has been reported as a strong predictor of cardiovascular
risk.26 However, the impact of hypothyroidism on CRP is
still controversial. Some studies have reported that CRP
levels are higher in patients with hypothyroidism than in
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healthy controls,27,28 whereas others have reported no
changes in CRP levels.6,29 In this study, we could not find
any significant differences in CRP levels according to the
thyroid function status. This finding is consistent with our
FMD results.
It is also consistent with other studies which indicated that
short-term hypothyroidism does not induce changes in the
more atherogenic small LDL particles30 and the antiathero-
genic protein adiponectin,24 suggesting that transient lipid
changes during short-term hypothyroidism may not induce
endothelial dysfunction in patients with low cardiac risk.
In conclusion, we demonstrated that short-term hypothy-
roidism after T4 withdrawal induced deleterious effects on
lipid profiles; however, it does not induce significant
changes in endothelial function. Thus, RAI using LT4
withdrawal can be safely used on patients with low cardio-
vascular risk.
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